Catalyst Biosciences (CBIO) Commences Phase 2/3 Trial of Marzeptacog Alfa (activated) for Prophylaxis in Hemophilia A or B with Inhibitors
Tweet Send to a Friend
Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the initiation and open enrollment of the Phase 2 part of the Phase ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
